Oncotarget recently #published this #trendingwithimpact editorial in Volume 14: “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” @MayoClinic https://t.co/WYOxJctGJZ #cancer #ovariancancer #drugdiscovery #research #oa #oncota
Oncotarget recently #published this #trendingwithimpact editorial in Volume 14: “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” @MayoClinic https://t.co/WYOxJctGJZ #cancer #ovariancancer #drugdiscovery #research #oa #oncota
#TrendingWithImpact: On December 22, 2023, researchers from @MayoClinic School of Medicine and Science #published a new #editorial in Oncotarget, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers” DOI: https://t.co/WYOx
Oncotarget recently #published this #trendingwithimpact editorial in Volume 14: “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” @MayoClinic https://t.co/WYOxJctGJZ #cancer #ovariancancer #drugdiscovery #research #oa #oncota
#PaperoftheDay: "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" DOI: https://t.co/fFu88TYgaJ #cancerresearch #oncology #MedEd
RT @Oncotarget: NEW #PaperoftheDay: "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" DOI: https://t.co/fFu88TY…
NEW #PaperoftheDay: "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" DOI: https://t.co/fFu88TYgaJ #cancerresearch #oncology #MedEd